Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase

Inclusion Criteria:

Meets 1 of the following disease-specific criteria:

Relapsed disease after =< 2 prior chemotherapy regimens (consolidation therapy excluded)
Primary-induction failure
Previously untreated and deemed unfit for or refusing cytotoxic chemotherapy
No hyperleukocytosis (leukemic blasts >= 30,000/mm^3)
No acute promyelocytic leukemia (M3)
No active CNS leukemia
SGOT and SGPT =< 2 times upper limit of normal (ULN)
Bilirubin normal
Creatinine =< 1.5 times ULN
No uncontrolled hypertension, congestive heart failure, angina pectoris, or ventricular dysrhythmias
Not pregnant or nursing
Negative pregnancy test
No uncontrolled disseminated intravascular coagulation

Fertile patients must use effective contraception

Hormonal contraception must have been initiated ≥ 1 month prior to study entry
No active graft-vs-host disease
No active uncontrolled infection
No intrinsic impaired organ function
No known allergy to imidazole drugs
No neuropathy >= grade 1
No known hypersensitivity to bortezomib, tipifarnib, boron, or mannitol
No physical or psychiatric conditions that would preclude study participation, including poorly controlled psychosis
At least 48 hours since prior hydroxyurea
No prior tipifarnib, bortezomib, or investigational proteasomal inhibitors
No concurrent radiotherapy, chemotherapy, or immunotherapy
No concurrent enzyme-inducing antiepileptic medications (e.g., phenytoin, phenobarbital, or carbamazepine)
ECOG performance status 0-2
LVEF >= 40%

Pathologically confirmed diagnosis of 1 of the following:

Acute myeloid leukemia
Acute lymphoblastic leukemia
Chronic myelogenous leukemia in blast phase